Hanall Biopharma (009420) — Long-term Investment Intensity
Hanall Biopharma (009420) has a Long-term Investment Intensity of 9.4% as of December 2019. Long-term investments of ₩17.93 Billion represent 9.4% of total assets of ₩191.38 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See Hanall Biopharma (009420) shareholders funds for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Hanall Biopharma Long-term Investment Intensity (2013–2019)
This chart shows how Hanall Biopharma's Long-term Investment Intensity has evolved across 7 annual periods from 2013 to 2019. As of December 2019, the intensity stands at 9.4%, reflecting long-term investments of ₩17.93 Billion against total assets of ₩191.38 Billion KRW. Also explore Hanall Biopharma balance sheet assets for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Hanall Biopharma (2013–2019)
The table below presents the year-by-year Long-term Investment Intensity for Hanall Biopharma from 2013 to 2019, covering 7 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Hanall Biopharma market cap and net worth.
| Year | LT Investment Intensity | LT Investments (KRW) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 9.4% | ₩17.93 Billion | ₩191.38 Billion | ▲ +5.6 pp |
| 2018 | 3.8% | ₩6.14 Billion | ₩162.30 Billion | ▲ +2.7 pp |
| 2017 | 1.0% | ₩1.76 Billion | ₩168.70 Billion | ▼ -0.4 pp |
| 2016 | 1.4% | ₩1.78 Billion | ₩124.73 Billion | ▲ +0.5 pp |
| 2015 | 0.9% | ₩1.06 Billion | ₩117.13 Billion | ▲ +0.6 pp |
| 2014 | 0.3% | ₩264.91 Million | ₩87.17 Billion | ▼ -0.5 pp |
| 2013 | 0.8% | ₩805.28 Million | ₩97.85 Billion | — |